BEAM * Stock Overview
A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Beam Therapeutics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$531.00 |
52 Week High | US$590.00 |
52 Week Low | US$440.00 |
Beta | 1.9 |
1 Month Change | 3.11% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -34.12% |
Recent News & Updates
Recent updates
Shareholder Returns
BEAM * | MX Biotechs | MX Market | |
---|---|---|---|
7D | 0% | 0% | 0% |
1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how BEAM * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how BEAM * performed against the MX Market.
Price Volatility
BEAM * volatility | |
---|---|
BEAM * Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in MX Market | 0% |
10% least volatile stocks in MX Market | 0% |
Stable Share Price: BEAM *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine BEAM *'s volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 472 | John Evans | beamtx.com |
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.
Beam Therapeutics Inc. Fundamentals Summary
BEAM * fundamental statistics | |
---|---|
Market cap | Mex$46.35b |
Earnings (TTM) | -Mex$2.88b |
Revenue (TTM) | Mex$7.02b |
6.6x
P/S Ratio-16.1x
P/E RatioIs BEAM * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BEAM * income statement (TTM) | |
---|---|
Revenue | US$349.64m |
Cost of Revenue | US$406.19m |
Gross Profit | -US$56.55m |
Other Expenses | US$87.04m |
Earnings | -US$143.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.80 |
Gross Margin | -16.17% |
Net Profit Margin | -41.07% |
Debt/Equity Ratio | 0% |
How did BEAM * perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 14:04 |
End of Day Share Price | 2024/11/25 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Beam Therapeutics Inc. is covered by 25 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Huidong Wang | Barclays |
Evan Seigerman | BMO Capital Markets Equity Research |
Konstantinos Biliouris | BMO Capital Markets Equity Research |